OTCPK:AXIM

Stock Analysis Report

Executive Summary

Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical, and cosmetic products.

Risk Analysis

Earnings have declined by -11.45% per year over past 5 years

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($680K)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 3 more risks


Snowflake Analysis

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has AXIM Biotechnologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AXIM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-19.2%

AXIM

2.5%

US Pharmaceuticals

2.0%

US Market


1 Year Return

-63.2%

AXIM

12.7%

US Pharmaceuticals

23.5%

US Market

Return vs Industry: AXIM underperformed the US Pharmaceuticals industry which returned 12.6% over the past year.

Return vs Market: AXIM underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

AXIMIndustryMarket
7 Day-19.2%2.5%2.0%
30 Day6.8%4.5%4.3%
90 Day-28.9%16.0%12.2%
1 Year-63.2%-63.2%15.6%12.7%26.1%23.5%
3 Year-96.9%-96.9%40.8%30.7%53.1%43.2%
5 Year-95.9%-95.9%29.5%15.8%75.5%56.1%

Price Volatility Vs. Market

How volatile is AXIM Biotechnologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is AXIM Biotechnologies undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether AXIM Biotechnologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AXIM Biotechnologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of AXIM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through AXIM Biotechnologies regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is AXIM Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AXIM Biotechnologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has AXIM Biotechnologies performed over the past 5 years?

-11.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AXIM is currently unprofitable.

Growing Profit Margin: AXIM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AXIM is unprofitable, and losses have increased over the past 5 years at a rate of -11.5% per year.

Accelerating Growth: Unable to compare AXIM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXIM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.8%).


Return on Equity

High ROE: AXIM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is AXIM Biotechnologies's financial position?


Financial Position Analysis

Short Term Liabilities: AXIM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AXIM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AXIM has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AXIM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: AXIM has a low level of unsold assets or inventory.

Debt Coverage by Assets: AXIM has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AXIM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AXIM has less than a year of cash runway if free cash flow continues to reduce at historical rates of -40.5% each year


Next Steps

Dividend

What is AXIM Biotechnologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.6%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AXIM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AXIM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AXIM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXIM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXIM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of AXIM Biotechnologies's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

John Huemoeller (64yo)

1yrs

Tenure

US$45,000

Compensation

Mr. John W. Huemoeller, II, has been Chief Executive Officer of AXIM Biotechnologies, Inc. since January 2, 2019 and serves as President. Mr. Huemoeller serves as the Chief Executive Officer of Novas. Mr.  ...


Management Age and Tenure

2.3yrs

Average Tenure

56yo

Average Age

Experienced Management: AXIM's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

4.8yrs

Average Tenure

64yo

Average Age

Experienced Board: AXIM's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.


Management Team

  • Robert Malasek (51yo)

    CFO & Secretary

    • Tenure: 3.6yrs
    • Compensation: US$247.00k
  • John Huemoeller (64yo)

    President

    • Tenure: 1yrs
    • Compensation: US$45.00k
  • George Anastassov (56yo)

    Founder & Chairman

    • Compensation: US$595.00k
  • Philip Van Damme (66yo)

    Chief Medical Officer & Director

    • Compensation: US$45.00k
  • Lekhram Changoer (52yo)

    CTO & Director

    • Compensation: US$475.00k

Board Members

  • Timothy Scott (66yo)

    Independent Director

    • Compensation: US$45.00k
  • John Huemoeller (64yo)

    President

    • Tenure: 1yrs
    • Compensation: US$45.00k
  • Robert Ritch

    Member of Advisory Board

    • Tenure: 3.1yrs
  • George Anastassov (56yo)

    Founder & Chairman

    • Compensation: US$595.00k
  • Philip Van Damme (66yo)

    Chief Medical Officer & Director

    • Compensation: US$45.00k
  • Lekhram Changoer (52yo)

    CTO & Director

    • Compensation: US$475.00k
  • Jacques Meis

    Member of Advisory Board

    • Tenure: 4.8yrs
  • John Zajicek

    Member of Advisory Board

    • Tenure: 5.3yrs
  • Renger Witkamp

    Member of Advisory Board

    • Tenure: 5.3yrs
  • Ilya Reznik

    Member of Advisory Board

    • Tenure: 3.1yrs

Company Information

AXIM Biotechnologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AXIM Biotechnologies, Inc.
  • Ticker: AXIM
  • Exchange: OTCPK
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$26.733m
  • Shares outstanding: 64.85m
  • Website: https://www.aximbiotech.com

Number of Employees


Location

  • AXIM Biotechnologies, Inc.
  • 45 Rockefeller Plaza
  • 20th Floor
  • New York
  • New York
  • 10111
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AXIMOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDApr 2013

Biography

Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical, and cosmetic products. It also engages in the extraction and purification of cannabinoids technologies based on its proprietary technologies. The company sells its products through Internet, direct-to-consumer health and wellness stores, collectives, cooperatives, and affiliate sales and master distributors. Axim Biotechnologies, Inc. was formerly known as Axim International Inc. and changed its name to Axim Biotechnologies, Inc. in July 2014. The company was founded in 2010 and is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/18 00:11
End of Day Share Price2020/01/17 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.